Predictors of cardiovascular disease in patients with chronic kidney disease VD stage treated with hemodialysis

Authors

  • I.M. Shifris SІ “Institute of Nephrology NAMS of Ukraine, Efferent technology department, Dehtiarivska str., 17-V, Kyiv, 04050, Ukraine, Ukraine https://orcid.org/0000-0002-9413-7301
  • I.O. Dudar SІ “Institute of Nephrology NAMS of Ukraine, Efferent technology department, Dehtiarivska str., 17-V, Kyiv, 04050, Ukraine, Ukraine https://orcid.org/0000-0002-4372-8240
  • Е.К. Krasiuk MNCE «Kyiv Сity Сenter of Nephrology and Dialysis», P. Zaporozhets str., 26, Kyiv, 02125, Ukraine, Ukraine
  • А.Yu. Shymova SІ “Institute of Nephrology NAMS of Ukraine, Efferent technology department, Dehtiarivska str., 17-V, Kyiv, 04050, Ukraine; MNCE «Kyiv Сity Сenter of Nephrology and Dialysis», P. Zaporozhets str., 26, Kyiv, 02125, Ukraine, Ukraine https://orcid.org/0000-0002-0575-6195

DOI:

https://doi.org/10.26641/2307-0404.2021.2.234513

Keywords:

chronic kidney disease V D stage, hemodialysis, cardiovascular diseases, coronary artery disease, predictors

Abstract

The aim of the study was to establish the frequency and possible predictors of cardiovascular disease (CVD) in chronic kidney disease (CKD) VD stage patients, treated with hemodialysis, based on results of prospective observation. The prospective observational cohort study  included 223 patients with CKD V D stage who were treated with hemodialysis (HD) during 2012-2019. The research was carried out in two stages. At the first stage, main demographic, laboratory and clinical characteristics of patients, including the frequency of CVD, at the time of beginning the study were examined. At the second stage, based on prospective studying of the dynamics of the frequency of CV pathology, an assessment of potential predictors of CVD in CKD V D stage patients treated with HD was made. Patients’ characteristics determined at the beginning of the study were used as possible predictors. The average duration of prospective study was 35.5±17.8 months, cumulative – 579.3 patient-years. For determination of prognostic factors of CVD events, ROC-analysis, univariate and multivariate Cox proportional hazard regression analysis were done. The primary endpoint (newly diagnosed CVDs) was assesses at the end of the study.  Statistical processing of the obtained results was performed using the MedCalc Statistical Software, version 19.3. During the study period, a significant increase of all CVD frequency by 80% (р<0.001) was stated, more than twice – of coronary artery disease (CAD; р<0.001) and atrial fibrillation (AF; р=0.0039). The incidence rate of CVD and CAD was 9.8 and 9.15 per 100-patient-years, respectively. The primary endpoint was observed in 92 (41.26%) patients: newly diagnosed CAD – in 53 patients, heart failure – in 12 patients, AF – in 9 patients, acute myocardial infarction – in 8 patients, other heart diseases – in 10 patients. Independent predictors on increased CVD risk in chronic kidney disease VD stage patients treated with hemodialysis are: age over 35 years, use of a central venous catheter as a vascular access during HD initiation, history of nasal MRSA collonization. In the other hand, serum albumin level of more than 36,6 g/l was associated with reduced risk.

References

Shifris IM, et al. [Аntimicrobial resistance of gram positive bacteria isolated іn patlents wlth chronic kidney disease stage 5D: prevalence and outcomes]. Ukrainskyi Zhurnal Nefrolohii ta Dializu. 2015;(2(46):31-40. Ukrainian. doi: https://doi.org/10.31450/ukrjnd.2(46).2015.02

Antomonov MYu. [Mathematical processing and analysis of biomedical data]. Kyiv: Medinform; 2018. p. 579. Russian.

[Treatment of patients with chronic kidney disease stage V GD. Adapted evidence-based clinical guidelines and unified clinical protocols]. Kyiv: «Polihraf plius». 2016. p. 228. Ukrainian.

[Order of the Ministry of Health of Ukraine of May 11, 2011 N 280/44 "On approval of the standard and unified clinical protocols for medical care in the specialty" nephrology"]. Kyiv; 2011. Ukrainian. Available from: https://ips.ligazakon.net/document/view/moz13528?ed=2011_05_11.

Bansal N. Evolution of Cardiovascular Disease During the Transition to End-Stage Renal Disease. Seminars in Nephrology. 2017;37(2):120-31. doi: https://doi.org/10.1016/j.semnephrol.2016.12.002

Cozzolino М, et al. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. Nephrol Dial Transplant. 2018;33:iii28-34. doi: https://doi.org/10.1093/ndt/gfy174

Ceretta ML, et al. Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation. 2018;33:1794-804. doi: https://doi.org/10.1093/ndt/gfx355

Mark J Sarnak, et al. CKD and Coronary Artery Disease: A KDIGO Conference Report. J Am Coll Cardiol. 2019;74(14):1823-38. doi: https://doi.org/10.1016/j.jacc.2019.08.1017

Liabeuf S, et al. Guideline attainment and morbidity/mortality rates in a large cohort of European haemodialysis patients (EURODOPPS). Nephrology Dialysis Transplantation. 2019;34(12):2105-10. doi: https://doi.org/10.1093/ndt/gfz049

Kovesdy CP. Clinical trials in end-stage renal disease-priorities and challenges. Nephrol Dial Transplant. 2019;34(7):1084-9. doi: https://doi.org/10.1093/ndt/gfz088

Malik J. Heart disease in chronic kidney disease – review of the mechanisms and the role of dialysis access. The Journal of Vascular Access. 2018;19(1):3-11. doi: https://doi.org/10.5301/jva.5000815

Harel Z, et al. Rehospitalizations and Emergency Department Visits after Hospital Discharge in Patients Receiving Maintenance Hemodialysis. J Am Soc Nephrol. 2015;26(12):3141-3150. doi: https://doi.org/10.1681/ASN.2014060614

Segall L-, Nistor I, Covic A. Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. BioMed Research International. 2014;Article ID 937398: 21 p. doi: http://dx.doi.org/10.1155/2014/937398

Shymova AU, Shifris IM, Korol LV, Dudar ІО. Nutritional Status and Indicators of Oxidative Stress among End-Stage Renal Disease Patients Treated with Continuous Ambulatory Peritoneal Dialysis. Prensa Med Argent. 2020;106(2):1-5. doi: https://doi.org/10.47275/0032-745X-178

Stepanova N, Burdeyna O. Association between Dyslipidemia and Peritoneal Dialysis Technique Survival. Open Access Maced J Med Sci. 2019;7(15):2467-73. PMID: 31666849; PMCID: PMC6814482. doi: https://doi.org/10.3889/oamjms.2019.664

Vervloet M, et al. The role of phosphate in kidney disease. Nat Rev Nephrol. 2017;13:27-38. doi: https://doi.org/10.1038/nrneph.2016.164

United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD. 2018. Available from: https://www.usrds.org/2018/view/Default.aspx

Published

2021-06-18

How to Cite

1.
Shifris I, Dudar I, Krasiuk Е, Shymova А. Predictors of cardiovascular disease in patients with chronic kidney disease VD stage treated with hemodialysis. Med. perspekt. [Internet]. 2021Jun.18 [cited 2024Apr.19];26(2):59-66. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/234513

Issue

Section

CLINICAL MEDICINE